Defeating anaemia in myelodysplastic syndromes: another step forward

Affiliations

Comment

Valeria Santini. Lancet Oncol. 2017 Oct.

. 2017 Oct;18(10):1290-1292.

doi: 10.1016/S1470-2045(17)30671-X. Epub 2017 Sep 1.

¹ Department of Hematology, AOU Careggi University of Florence, Florence 50134, Italy. Electronic address: santini@unifi.it.

No abstract available

Comment on

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Platzbecker U, et al. Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Lancet Oncol. 2017. PMID: 28870615 Clinical Trial.